Literature DB >> 11224440

Differential involvement of D1 and D2 dopamine receptors in the expression of morphine withdrawal signs in rats.

M. Funada1, T.S. Shippenberg.   

Abstract

The role of dopamine (DA) receptors in the expression of opioid dependence was examined by use of an unbiased conditioned place preference paradigm. Male Sprague-Dawley rats were implanted s.c. with two pellets containing placebo or 75mg morphine. Animals received one conditioning session with saline and one with the DA D1 receptor antagonist SCH23390 (0.01-0.05mg, s.c.) or the DA D2 receptor antagonist raclopride (0.25-1.0mg/kg, s.c.). Conditioning sessions were conducted 4 days after pellet implantation. During each of these sessions, physical signs of withdrawal were quantified. In morphine-pelleted animals, the D2 receptor antagonist raclopride produced conditioned place aversions, with a minimum effective dose of 0.5mg/kg. Administration of a higher dose also resulted in wet-dog shakes, ptosis and diarrhea in morphine-pelleted animals. This effect was not observed in response to lower doses of raclopride or in placebo-pelleted animals. The D1 receptor antagonist SCH23390 failed to produce conditioned place aversions in either morphine- or placebo-pelleted animals after single-trial conditioning. This antagonist was also ineffective in producing physical withdrawal signs. After two conditioning sessions with SCH23390, both the morphine- and placebo-pelleted animals exhibited a marked aversion for the SCH23390-paired place. However, there was no difference between groups in the magnitude of this effect. These data demonstrate that the acute blockade of D2 receptors produces aversive effects in opioid-dependent animals and that this effect occurs in the presence of few, if any, prototypic physical withdrawal signs. Furthermore, the inability of a selective D1 receptor antagonist to produce conditioned aversive effects or physical signs of withdrawal suggests an important role of D2 as compared to D1 receptors in the expression of morphine withdrawal signs.

Entities:  

Year:  1996        PMID: 11224440

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  7 in total

Review 1.  Neural systems underlying opiate addiction.

Authors:  Taco J De Vries; Toni S Shippenberg
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

Review 2.  Hypocretin/orexin involvement in reward and reinforcement.

Authors:  Rodrigo A España
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

3.  Effect of glutamate receptor antagonists on place aversion induced by naloxone in single-dose morphine-treated rats.

Authors:  Yoichi Kawasaki; Chunyu Jin; Katsuya Suemaru; Hiromu Kawasaki; Kazuhiko Shibata; Tominari Choshi; Satoshi Hibino; Yutaka Gomita; Hiroaki Araki
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

4.  Dopamine involved in the nociceptive modulation in the parafascicular nucleus of morphine-dependent rat.

Authors:  H R Gao; T F Shi; C X Yang; G W Zhang; D Zhang; R S Jiao; Y Zhang; M Y Xu; H Zhu
Journal:  Neurochem Res       Date:  2011-10-14       Impact factor: 3.996

5.  Nicotine attenuates place aversion induced by naloxone in single-dose, morphine-treated rats.

Authors:  Hiroaki Araki; Ken-ya Kawakami; Chunyu Jin; Katsuya Suemaru; Yoshihisa Kitamura; Mari Nagata; Koujiro Futagami; Kazuhiko Shibata; Hiromu Kawasaki; Yutaka Gomita
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

6.  Addicting drugs utilize a synergistic molecular mechanism in common requiring adenosine and Gi-beta gamma dimers.

Authors:  Lina Yao; Peidong Fan; Zhan Jiang; William S Mailliard; Adrienne S Gordon; Ivan Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-06       Impact factor: 11.205

7.  Some effects of dopamine transporter and receptor ligands on discriminative stimulus, physiologic, and directly observable indices of opioid withdrawal in rhesus monkeys.

Authors:  Lance R McMahon; Jun-Xu Li; F Ivy Carroll; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2008-07-18       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.